Orbimed Advisors LLC executed the largest insider purchase in Q32 Bio's history by buying $10 million worth of shares at $8.00 per share, signaling strong conviction in the biotech's near-term prospects. This high-profile transaction comes as the stock has rallied nearly 37% over the last 90 days and recently secured a $55 million private placement.
Price context
QTTB is currently trading at $6.69, representing a 36.81% gain over the last 90 days and sitting 14.23% below its 52-week high of $7.80.
Catalysts to watch
- •The $55 million private placement announced on May 27, 2026, provides capital to advance the alopecia areata pipeline.
- •SIGNAL-AA study data is expected in mid-2026, which could drive further valuation expansion.
- •Wall Street analysts have set a consensus price target indicating 145.69% upside potential as of May 26, 2026.
Risks
- •Short interest represents 7.77% of the float, creating potential volatility if the stock reverses course.
- •The stock is currently trading 14.23% below its 52-week high of $7.80, leaving room for downside if momentum slows.
AI-generated context from public data. Not investment advice. Verify before trading.